GlassScriptPhysician profile
Barry N Straus
NPI 1447252861
$3,890.76
in general payments reported to CMS, 2019-2025
28 companies · $377 in 2025
The $377 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $619 · 2021: $833 · 2022: $501 · 2023: $941 · 2024: $170 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988 · Grant: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.90 |
| Grant | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $768.33 | 2019-2025 | Relistor |
| Boston Scientific Corporation | $500.00 | 2023 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $493.99 | 2021-2025 | Qulipta, Ubrelvy |
| Forte Bio-Pharma LLC | $468.57 | 2019-2025 | Prolate, Nalocet, Tanlor |
| Allergan, INC. | $238.43 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $155.02 | 2021 | |
| Pfizer INC. | $148.23 | 2019-2023 | |
| Collegium Pharmaceutical, INC. | $140.53 | 2019-2023 | Xtampza |
| Supernus Pharmaceuticals, INC. | $123.28 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $108.85 | 2019-2021 | |
| Lilly USA, LLC | $94.98 | 2019-2022 | |
| Daiichi Sankyo INC. | $69.65 | 2019 | |
| Amgen INC. | $62.89 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $61.03 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.06 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $58.05 | 2020-2021 | |
| Sentynl Therapeutics, INC. | $57.27 | 2019 | |
| Impel Pharmaceuticals INC. | $49.01 | 2022-2023 | Trudhesa |
| Hikma Pharmaceuticals USA | $48.01 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $41.16 | 2019-2022 | |
| Kaleo, INC. | $32.55 | 2019 | |
| Scilex Pharmaceuticals INC. | $18.21 | 2025 | |
| Redhill Biopharma INC. | $18.17 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.83 | 2022 | |
| Ibsa Pharma INC. | $15.24 | 2020 | |
| Grt US Holding, INC. | $14.33 | 2020 | |
| Virtus Pharmaceuticals LLC | $13.99 | 2023 | Levorphanol Tartrate |
| Protega Pharmaceutials INC | $13.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Straus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.